Cirrhosis Hepatic Encephalopathy
Conditions
Interventions
Embolization group:Interventional embolization combined with standard medical therapy
Sponsors
Mengchao Hepatobiliary Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Clear diagnosis of cirrhosis accompanied by persistent or recurrent hepatic encephalopathy (HE); 2. Definite presence of spontaneous portal shunts with a diameter larger than 10 mm, confirmed through imaging; 3. Age between 18 and 75 years (inclusive), with no gender restrictions; 4. Mandatory requirement for routine blood tests: hemoglobin (HB) levels >= 80g/L, absolute neutrophil count (ANC) >= 1.5 x 10^9/L, and platelet count (PLT) >= 50 x 10^9/L; 5. Anticipated life expectancy of more than 6 months; 6. Willingness to participate voluntarily in this clinical trial and ability to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Presence of comorbid malignancies; 2. History of splenic artery embolization, splenectomy, hepatectomy, liver transplantation, or surgical shunt; 3. History of transjugular intrahepatic portosystemic shunt (TIPS); 4. Child-Pugh score > 13; 5. Presence of refractory ascites; 6. Presence of active gastrointestinal bleeding; 7. Presence of psychiatric or neurological disorders; 8. Presence of other severe cardiopulmonary or renal diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HE-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Changes in liver function;Safety; | — |
Countries
China
Contacts
Public ContactGuo Wuhua
Mengchao Hepatobiliary Hospital of Fujian Medical University
Outcome results
None listed